Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Yoshihiro Inamoto, Igor Petriček, Linda Burns, Saurabh Chhabra, Zack DeFilipp, Peiman Hematti, Alicia Rovó, Raquel Schears, Ami Shah, Vaibhav Agrawal, Aisha Al-Khinji, Ibrahim Ahmed, Asim Ali, Mahmoud Aljurf, Hassan Alkhateeb, Amer Beitinjaneh, Neel Bhatt, Dave Buchbinder, Michael Byrne, Natalie CallanderKristina Fahnehjelm, Nosha Farhadfar, Robert Peter Gale, Siddhartha Ganguly, Gerhard C. Hildebrandt, Erich Horn, Ann Jakubowski, Rammurti T. Kamble, Jason Law, Catherine Lee, Sunita Nathan, Olaf Penack, Ravi Pingali, Pinki Prasad, Drazen Pulanic, Seth Rotz, Aditya Shreenivas, Amir Steinberg, Khalid Tabbara, André Tichelli, Baldeep Wirk, Jean Yared, Grzegorz W. Basak, Minoo Battiwalla, Rafael Duarte, Bipin N. Savani, Mary E.D. Flowers, Bronwen E. Shaw, Nuria Valdés-Sanz

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment, and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complicastions and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.

Original languageEnglish (US)
Pages (from-to)648-661
Number of pages14
JournalBone Marrow Transplantation
Volume54
Issue number5
DOIs
StatePublished - May 1 2019

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Inamoto, Y., Petriček, I., Burns, L., Chhabra, S., DeFilipp, Z., Hematti, P., Rovó, A., Schears, R., Shah, A., Agrawal, V., Al-Khinji, A., Ahmed, I., Ali, A., Aljurf, M., Alkhateeb, H., Beitinjaneh, A., Bhatt, N., Buchbinder, D., Byrne, M., ... Valdés-Sanz, N. (2019). Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 54(5), 648-661. https://doi.org/10.1038/s41409-018-0339-6